Idsk -- TORONTO (EGMN) – Patients with osteoporosis who are on bisphosphonate therapy clearly face an increased treatment-linked risk for an atypical femur fractures, but at a low rate that is dwarfed by the number of typical hip fractures the drugs prevent.
